Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

The addition of zovegalisib (RLY-2608), a PI3Kα inhibitor, to fulvestrant (Faslodex) exhibited beneficial efficacy among patients with PIK3CA-mutated hormone receptor (HR)–positive/HER2-negative advanced breast cancer who experienced…